Communiqués Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Temps Différé Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
25,59 ^USD	+0,08%		0,00%	+58,65%

11/06	Deciphera Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI
03/06	Deciphera Pharmaceuticals annonce la présentation orale des résultats de l'étude pivotale de phase 3 Motion sur le vimseltinib chez les patients atteints de tumeur à cellules géantes ténosynoviale (TGCT) lors de la réunion annuelle 2024 de l'Asco et la publication en ligne dans le Lancet	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	03/06	BU
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH	02/05	BU
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH	29/04	PR
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.	29/04	PR
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders	29/04	BU
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	29/04	BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)	18/04	PR
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	09/04	BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	27/02	BU
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results	06/02	BU
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	01/02	BU
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02	BU
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	18/01	BU
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe	10/01	AQ
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company	08/01	BU
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	05/01	BU
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	BU
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit	29/11	BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	07/11	BU
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT	31/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Communiqués

Filtres